Join Now

Category Archives: BioUtah News

Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes

By Natalie Themm | Published March 31, 2022

Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes

| Tagged | Leave a comment

Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors

By Natalie Themm | Published March 31, 2022

Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors

| Tagged | Leave a comment

PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update

By Natalie Themm | Published March 31, 2022

SALT LAKE CITY, March 30, 2022 /PRNewswire/ — PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the twelve-month period ended December 31, 2021. Recent Business and Financial Updates In the first quarter of 2022, PolarityTE received approval from the U.S. […]

| Tagged | Leave a comment

Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed Capital

By Natalie Themm | Published March 31, 2022

The total capital represents the largest seed financing for life science startups in Utah’s history

| Tagged | Leave a comment

Halia Therapeutics Presented Data on Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer’s Disease

By Natalie Themm | Published March 31, 2022

Halia Therapeutics presented data today on its NLRP3 inhibitor program at today’s 10th Annual Neurodegenerative Drug Development Summit. 

| Tagged | Leave a comment

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022

By Natalie Themm | Published March 31, 2022

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022

| Tagged | Leave a comment

Pfizer’s $7B bet delivers phase 3 success, advancing bid to establish new drug in ulcerative colitis Arena

By Natalie Themm | Published March 24, 2022

Pfizer’s $6.7 billion bet on Arena Pharmaceuticals has delivered a phase 3 success.

| Tagged | Leave a comment

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results

By Natalie Themm | Published March 24, 2022

Recursion reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2021.

| Tagged | Leave a comment

FierceBiotech recognizes Recursion as the #2 Biotech IPO of 2021!

By Natalie Themm | Published March 24, 2022

FierceBiotech Special Report: The top 10 biotech IPOs of 2021

| Tagged | Leave a comment

Co-Diagnostics Reports Full Year 2021 Financial Results

By Natalie Themm | Published March 24, 2022

Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY’22

| Tagged , | Leave a comment

WATCH THE EXIM BANK & STEP GRANT FUNDS 101 WEBINAR REPLAY

By Lori Ross | Published March 18, 2022

WTC UTAH HAS A RECORD $1M+ TO ADMINISTER TO UTAH SMALL BUSINESSES. Learn from World Trade Center Utah, Meridian Finance Group, and the U.S. Small Business Administration (SBA) about export programs through the Export-Import Bank of the United States (EXIM) and how State Trade Expansion Program (STEP) funds can be used for those programs as a new eligible expense.

| Leave a comment

Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board

By Natalie Themm | Published March 17, 2022

Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board

| Tagged , | Leave a comment

A Special Thanks To Our Legacy and Platinum Elite Members